Reunion Neuroscience’s psychedelic has reduced the symptoms of postpartum depression in a phase 2 study, setting up the biotech to launch a late-stage trial next year. The drug in question is RE104, a ...
Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback